Equity Research
William Blair research analyst Sharon Zackfia was featured on CNBC during William Blair’s Growth Stock Conference, where she discussed many of the restaurant brands on her coverage list and the macroeconomic factors impacting the sector so far in 2025.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Contineum Therapeutics, Inc. (CTNM $3.93), a clinical-stage biotech developing small-molecule therapeutics for high-unmet-need indications in the prevalent neuroinflammation and immunology space.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
